Elizabeth Eaton’s Post

Biotech innovations are driving new treatments for pancreatic cancer, one of the deadliest cancers. A blood test now detects early-stage pancreatic cancer with 97% accuracy. Impact - ▪️ Oncolytics Biotech: Pelareorep advances with FDA Fast Track designation and $5M award. ▪️ Candel Therapeutics: CAN-2409 doubles median survival in phase 2 trials. ▪️ ABVC BioPharma: New collaboration with OncoX aims to deliver transformative treatments. Think About - ▪️ How will early detection tests reshape treatment? ▪️ Can biotech collaborations set new therapy standards?

🌟 Major Step Forward in Cancer Treatment: Angiex has officially dosed the first patient in its Phase 1 trial of a novel ADC (antibody-drug conjugate) therapy. 💉 This trial marks an important milestone in the development of targeted cancer therapies, potentially offering a new lifeline for patients facing tough-to-treat cancers. As Angiex continues to advance this promising therapy, the biopharma industry is watching closely. 🔍 #ClinicalTrials #CancerTreatment #ADCTherapy #Biopharma #OncologyInnovation 🔗 Explore the details of this exciting trial and its potential impact on cancer care: https://lnkd.in/e5JSkJHA

The AACR 2024 is underway, and we are here on-site to present progress in our oncology pipeline! Here are some key highlights: ✔ PRMT5 Inhibitors show potential best-in-class profiles, including a strong antiproliferative effect on MTAP-deleted cell lines and a good safety window versus MTAP WT cells. ✔WRN Inhibitor Program demonstrates target engagement and selective potency with a synthetic lethal effect; in vivo efficacy studies exhibited pronounced tumor growth inhibition in an MSI-H colorectal cancer xenograft model. ✔ONCO Prime Discovery Platform recently received a PLN 26 million (approx. USD 6.6 million) grant from the Polish Agency for Enterprise Development. It has identified novel drug targets in KRAS-mutant patient-derived cells (PDCs) with therapeutic potential in colorectal cancer. The ONCO Prime platform has broad potential across multiple tumor types. ✔RVU120 shows efficacy both as a monotherapy and synergistically in combination with ruxolitinib in preclinical models of myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. ✔MEN1703 (SEL24), presented by our partner Menarini Group, shows cytotoxic activity in myelofibrosis cell lines as monotherapy and synergistically in combination with ruxolitinib. Read more: https://lnkd.in/dkK6c8QX See the posters: https://lnkd.in/gJuXXfH You can still catch us at the AACR Annual Meeting in San Diego, where we showcase these exciting developments in oncology therapeutics!  See you there! #AACR2024 #AACRAnnualMeeting #RyvuTherapeutics #CancerResearch #DiscoverForPatients

Astellas Pharma US and Kelonia Therapeutics Team Up to Revolutionize CAR-T Therapy! Great news for cancer patients! Astellas Pharma and Kelonia Therapeutics have joined forces to develop next-generation CAR-T cell therapies using innovative technologies. What's the deal? Xyphos, a subsidiary of Astellas, will combine their ACCEL™ technology (improves CAR-T therapy control) with Kelonia's iGPS® system (delivers genes precisely within the body). This powerful combo aims to create in vivo CAR-T therapies, meaning the treatments happen inside the patient's body, potentially offering greater convenience and efficiency. The collaboration focuses on two cancer programs, with potential for expansion. Why is this exciting? CAR-T therapies have shown immense promise in treating cancer, but face challenges like complex manufacturing and limited control. This collaboration tackles these challenges, potentially leading to more effective and accessible CAR-T treatments. This advancement could benefit patients with various solid and blood cancers. What's next? The companies will work together to develop and commercialize these innovative therapies. This collaboration represents a significant step forward in revolutionizing CAR-T therapy and offering new hope for cancer patients. Stay tuned! This partnership holds immense potential for the future of cancer treatment. #cancerresearch #CAR-Ttherapy #innovation #collaboration #makingadifference

🚀 Breaking news in the pharma world! Boehringer Ingelheim has acquired Nerio Therapeutics for up to $1.3 billion, significantly bolstering our immuno-oncology pipeline. This acquisition includes Nerio’s advanced preclinical program, which will be a cornerstone in developing innovative cancer treatments. 💡 Nerio Therapeutics, known for its pioneering work with phosphatases, brings to the table novel checkpoint inhibitors that expand our repertoire of potential cancer therapies. As Paola Casarosa, a member of our board of managing directors, stated, this move creates a broad panel of exciting new cancer treatment combination opportunities. 🧬 We’re thrilled to integrate Nerio’s small molecule PTPN1/N2 inhibitors into our portfolio. These inhibitors are designed to activate the immune system to combat cancer cells, offering a first-in-class opportunity with superior drug-like properties. This acquisition aligns perfectly with our mission to extend the benefits of immuno-oncology to more patients, potentially providing single-agent therapy solutions. 👏 A big shoutout to Sanford Madigan, co-founder and CEO of Nerio Therapeutics, and his team for their groundbreaking work. We’re excited to continue this journey together and unlock the full potential of these compounds in the fight against cancer. #BoehringerIngelheim #NerioTherapeutics #ImmunoOncology #CancerResearch #PharmaInnovation #Healthcare

Noxopharm Limited (ASX:NOX, OTC:NOXOF), an innovative #biotech company, has soared on new data regarding its CRO-67 preclinical drug for #PancreaticCancer that shows significantly reduced pancreatic tumours and barrier cells in a complex model. Pancreatic cancer is especially difficult to treat because tumours are surrounded by a dense barrier of cells that protects them from anti-cancer drugs, as well as from the body’s immune system. CRO-67 targets pancreatic cancer in a different and innovative way by acting as a novel dual-cell therapy, destroying both tumour and barrier cells. Investors reacted positively with shares as much as 48.81% higher in ASX trading this morning to A$0.125, a 2024 high. “We are very pleased with the outcome of these studies as they show that CRO-67 continues to have a dual-cell therapy effect in a variety of pancreatic cancer models, including this complex model where the bar is set much higher," Noxopharm CEO Dr Gisela Mautner said. “Pancreatic cancer has a very poor survival rate. There is clearly an unmet need to develop new treatments, either alone or in combination with existing treatments, to help alleviate patient suffering and help save many lives.” More at #Proactive #ProactiveInvestors #Biopharmaceutcials #Oncology #CellTherapy #NOX http://ow.ly/yqMP105FlYn

Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment: Silexion’s (NASDAQ:SLXN) New analysis reveals improved resectability and response rates, providing hope for patients with one of the deadliest cancer types—and potentially much more. Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing cutting-edge RNA interference (RNAi) therapies, has announced … Continue reading → #Finance #FinancialMarket #PersonalFinance #PharmaceuticalsBiotech

I am pleased to announce that we presented the preclinical discovery of NKT3964, a potential first-in-class oral CDK2-selective degrader, during the ‘Posters in the Spotlight’ session at the EORTC-NCI-AACR Triple Conference. This is the second molecule in our uniquely broad and deep CDK2(/4) franchise to enter clinical development. We hold strong conviction in CDK2(/4) as oncology targets for both monotherapy and combination therapies. Our potential first-in-class degraders have the potential to challenge current treatment paradigms for breast cancer and solid tumors with cyclin E amplification/overexpression. Our goal is to become a significant player in this space. Today’s presentation also highlights our expertise in developing oral PROTAC degraders—a game-changing modality offering remarkable potency and selectivity, with the potential for a wider therapeutic window. https://lnkd.in/g5GynC29

#News: Halda Therapeutics, a Connecticut-based biotech founded by Yale professor and entrepreneur Craig Crews, announced Monday that it has raised $126 million in a #SeriesB extension to move two candidates into #clinicaltrials for patients with #prostate and #breast #cancer. The #biotech has been developing a new class of #cancertherapies known as #RegulatedInducedProximityTargetingChimeras (RIPTAC). According to Halda, these assets use a “hold and kill” mechanism using two proteins, one cancer-specific and one with an essential function. The candidates are designed to help retract essential cell function and cause the death of the cancer cells while preserving non-cancer tissue. “This financing will enable us to bring to patients our oral, selective and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Kat Kayser-Bricker, Halda chief scientific officer, said in a statement. Read more from BioSpace 👇🏼